NDA 12708, held by Medpointe Pharm Hlc. Methyclothiazide; Reserpine.
As of Nov 14, 2026, NDA 12708 (Diutensen-R), held by Medpointe Pharm Hlc, was not approved, with 1 approved supplement and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Diutensen-R2.5MG;0.1MG ยท tablet;oral | Methyclothiazide; Reserpine | Discontinued |
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 30, 1975 | Supplement 9Labeling | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters